Silvana Marcussi

Dr. Silvana Marcussi


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Toxicon
Verified
Journal Article
Closed access
SMSilvana Marcussi
Silvana Marcussi
RSRodrigo Stabeli
Rodrigo Stabeli
NSNorival A. Santos-Filho
Norival A. Santos-Filho
DMDanilo Menaldo
Danilo Menaldo
LPLuciana L. Silva Pereira
Luciana L. Silva Pereira
ASAndreimar Soares
Andreimar Soares

1 September 2011 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
SMSilvana Marcussi
Silvana Marcussi
PSPaulo R.S. Santos
Paulo R.S. Santos
DMDanilo Menaldo
Danilo Menaldo
LSLucas B. Silveira
Lucas B. Silveira
NSNorival A. Santos-Filho
Norival A. Santos-Filho
ASAndreimar Soares
Andreimar Soares

1 September 2018 in Environmental Toxicology and Pharmacology
Verified
Journal Article
Closed access
TCTássia Flávia Dias Castro
Tássia Flávia Dias Castro
JSJosé Gilmar da Silva Souza
José Gilmar da Silva Souza
ACAline Ferreira Souza de Carvalho
Aline Ferreira Souza de Carvalho
IAIsadora de Lima Assis
Isadora de Lima Assis
MPMarcel Palmieri
Marcel Palmieri
LMLuis David Solis Murgas
Luis David Solis Murgas

25 October 2017 in Toxins
Verified
Journal Article
Open access
PDF file
TSThais Sales
Thais Sales
SMSilvana Marcussi
Silvana Marcussi
ECElaine F. F. Da Cunha
Elaine F. F. Da Cunha
Kamil KucaKamil Kuca
Kamil Kuca
TRTeodorico C. Ramalho
Teodorico C. Ramalho
Human phospholipase A2 (hPLA2) of the IIA group (HGIIA) catalyzes the hydrolysis of membrane phospholipids, producing arachidonic acid and originating potent inflammatory mediators. Therefore, molecules that can inhibit this enzyme are a source of potential anti-inflammatory drugs, with different action mechanisms of known anti-inflammatory agents. For the study and development of new anti-inflammatory drugs with this action mechanism, snake venom PLA2 (svPLA2) can be employed, since the svPLA2 has high similarity with the human PLA2 HGIIA. Despite the high similarity between these secretory PLA2s, it is still not clear if these toxins can really be employed as an experimental model to predict the interactions that occur with the human PLA2 HGIIA and its inhibitors. Thus, the present study aims to compare and evaluate, by means of theoretical calculations, docking and molecular dynamics simulations, as well as experimental studies, the interactions of human PLA2 HGIIA and two svPLA2s, Bothrops toxin II and Crotoxin B (BthTX-II and CB, respectively). Our theoretical findings corroborate experimental data and point out that the human PLA2 HGIIA and svPLA2 BthTX-II lead to similar interactions with the studied compounds. From our results, the svPLA2 BthTX-II can be used as an experimental model for the development of anti-inflammatory drugs for therapy in humans.

24 August 2020 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
PDF file
PCPedro H. S. Cesar
Pedro H. S. Cesar
MTMarcus V. C. Trento
Marcus V. C. Trento
IKIsaac Konig
Isaac Konig
SMSilvana Marcussi
Silvana Marcussi

23 April 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
PCPedro H. S. Cesar
Pedro H. S. Cesar
MTMarcus Vinícius Cardoso Trento
Marcus Vinícius Cardoso Trento
TSThais Sales
Thais Sales
TMTamara R. Marques
Tamara R. Marques
MBMariana A. Braga
Mariana A. Braga
SMSilvana Marcussi
Silvana Marcussi